TIPS Combined With Lenvatinib and PD-1 Inhibitor for Advanced HCC With Main Trunk PVTT

NARecruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

October 1, 2024

Primary Completion Date

December 1, 2026

Study Completion Date

August 30, 2027

Conditions
Hepatocellular CarcinomaPortal Vein Tumor ThrombusSystemic Therapy
Interventions
PROCEDURE

Transjugular intrahepatic portosystemic shunt

A needle punctured the portal vein through the transjugular approach. After a successful puncture, the parenchymal tract was dilated, and covered stents were introduced. The specifications of the covered stents were 8 mm × 50 mm, 8 mm × 60 mm, 8 mm × 70 mm, and 8 mm × 80 mm. All of the diameters of the bare stents were 8 mm, and the lengths were 50-80 mm. The portal vein pressure was measured before and after shunt creation. After the insertion of TIPS, all of the participants received a diuretic treatment and a salt-limited diet.

DRUG

Lenvatinib

12 mg (body weight ≥60 kg) , 8 mg (body weight \<60 kg

DRUG

PD-1 inhibitor

Tislelizumab (200mg intravenously every 3 weeks), Sintilimab (200mg intravenously every 3 weeks), Camrelizumab (200mg intravenously every 3 weeks)

Trial Locations (1)

100853

RECRUITING

Chinese PLA General hospital, Beijing

All Listed Sponsors
collaborator

Chinese PLA General Hospital

OTHER

lead

Sun Yat-sen University

OTHER